Hospital
Naples Hma LLC
Naples Hma LLC was paid $2.22M by Medicaid between Jan 2018 and Oct 2024, across 108 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoNAPLES HMA LLC
NAPLES, FL 34119
NAPLES, FL 34119
33aNPI1316992134assigned 05/23/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.22M
24GClaims155,204
24DCodes billed108
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#116 of 163
Median peer was paid$4.77M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,769 | $173K | |
| 2019 | 27,457 | $313K | |
| 2020 | 23,612 | $242K | |
| 2021 | 37,610 | $499K | |
| 2022 | 38,980 | $732K | |
| 2023 | 13,212 | $246K | |
| 2024incomplete | 564 | $15K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 6,197 | 5,134 | $341K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 5,681 | 4,913 | $314K |
| 36415 | Collection of venous blood by venipuncture | 13% | 14,016 | 9,258 | $298K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.6% | 996 | 871 | $168K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.9% | 3,540 | 2,886 | $154K |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.4% | 3,386 | 2,574 | $143K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.9% | 1,259 | 1,067 | $131K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.8% | 2,160 | 1,762 | $129K |
| G0378 | Hospital observation service, per hour | 5.3% | 1,141 | 911 | $117K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.9% | 2,033 | 1,753 | $64K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 811 | 716 | $48K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 1,162 | 267 | $27K |
96 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,141 | $18K |
| 99218 | <1% | 145 | $14K | |
| 80053 | Comprehensive metabolic panel | <1% | 10,384 | $14K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,979 | $11K |
| 81025 | <1% | 2,175 | $11K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,454 | $9K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,001 | $9K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,815 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,939 | $8K |
| 87400 | <1% | 412 | $8K | |
| 82962 | <1% | 2,945 | $8K | |
| 94760 | <1% | 3,474 | $8K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,195 | $8K |
| 85610 | <1% | 3,764 | $8K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 225 | $7K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,413 | $7K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 249 | $7K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 43 | $6K |
| 84484 | <1% | 5,066 | $6K | |
| 83735 | <1% | 3,590 | $6K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 40 | $6K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 879 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,865 | $6K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,934 | $6K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 404 | $5K |
| 85027 | <1% | 2,440 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,440 | $4K |
| 81001 | <1% | 3,092 | $4K | |
| 81003 | <1% | 2,059 | $4K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 418 | $4K |
| 83690 | <1% | 3,165 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 634 | $4K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,825 | $3K |
| 87428 | <1% | 1,339 | $3K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 485 | $3K |
| 85730 | <1% | 2,698 | $3K | |
| 80061 | Lipid panel | <1% | 1,665 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,701 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 429 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 222 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 198 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 400 | $2K |
| 96376 | <1% | 504 | $2K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 253 | $1K |
| 97161 | <1% | 60 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,354 | $1K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,880 | $1K |
| 87430 | <1% | 117 | $1K | |
| 86850 | <1% | 89 | $1K | |
| 83880 | <1% | 1,484 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 272 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,628 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,101 | $879.21 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 23 | $855.35 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 23 | $855.35 |
| 84439 | <1% | 106 | $789.89 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 23 | $698.97 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 175 | $620.19 |
| 82550 | <1% | 427 | $600.30 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,393 | $577.99 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $432.69 |
| G1002 | Clinical decision support mechanism medcurrent, as defined by the medicare appropriate use criteria program | <1% | 332 | $350.46 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 664 | $225.67 |
| 85379 | <1% | 353 | $137.67 | |
| 88342 | <1% | 37 | $105.53 | |
| 82248 | <1% | 87 | $89.72 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 268 | $88.13 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 14 | $72.41 |
| 87040 | <1% | 228 | $70.14 | |
| 83605 | <1% | 455 | $53.72 | |
| 94664 | <1% | 63 | $51.72 | |
| 87186 | <1% | 168 | $30.48 | |
| 87077 | <1% | 171 | $29.58 | |
| 86900 | <1% | 134 | $17.02 | |
| 86901 | <1% | 134 | $17.02 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 146 | $9.72 |
| 86140 | <1% | 141 | $6.33 | |
| 82043 | <1% | 25 | $3.09 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 392 | $0.00 |
| 84100 | 0% | 117 | $0.00 | |
| 80179 | 0% | 16 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 80 | $0.00 |
| 84702 | 0% | 29 | $0.00 | |
| 80143 | 0% | 17 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 13 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 13 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 616 | $0.00 |
| 82077 | 0% | 258 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 77 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 12 | $0.00 |
| 80069 | 0% | 12 | $0.00 | |
| C1769 | Guide wire | 0% | 15 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 26 | $0.00 |
| 82607 | 0% | 18 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 13 | $0.00 |
| 84703 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.